
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a clinical-stage biotechnology company with a strong pipeline of therapeutics aimed at degrading disease-causing proteins and treating a variety of serious diseases. With several promising programs in different stages of development and key partnerships in place, the company is well-positioned for success in the oncology and neuroscience markets. While there are risks inherent in the biotechnology industry, Arvinas's innovative approach and team of experts make it a solid investment for those looking for growth potential.
Bears say
Arvinas is experiencing a significant shift with the introduction of new CEO Randy Teel and a change in drug development philosophy, leading to a more focused and cohesive pipeline. The new strategy includes a clear focus on partnering earlier in the programs' lifecycles and a focus on both validated and novel targets, which could provide a differentiated profile. However, the company still faces challenges in narrowing its overall portfolio and successfully developing its product candidates.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares